Static and dynamic electrocardiographic patterns preceding torsades de pointes in the acquired and congenital long QT syndrome
暂无分享,去创建一个
W Zareba | J Xia | JP Couderc | X Xu | S Kaab | M Hinteeser
[1] C Antzelevitch,et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.
[2] R. Shah,et al. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.
[3] Michael J Ackerman,et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. , 2010, Circulation.
[4] P. Coumel,et al. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. , 1995, Journal of the American College of Cardiology.
[5] J. Couderc. The telemetric and holter ECG warehouse initiative (THEW): A data repository for the design, implementation and validation of ECG-related technologies , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.
[6] D. Roden. A practical approach to torsade de pointes , 1997, Clinical cardiology.
[7] Borje Darpo,et al. Electrocardiographic Identification of Drug‐Induced QT Prolongation: Assessment by Different Recording and Measurement Methods , 2004, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[8] Michael Glikson,et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. , 2007, Journal of the American College of Cardiology.
[9] C Antzelevitch,et al. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. , 1994, Journal of the American College of Cardiology.
[10] L. Hondeghem. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability). , 2005, Novartis Foundation symposium.